News Releases

2020

R&D
Feb.17.2020
Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma (116KB)
R&D
Feb.17.2020
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (118KB)
R&D
Feb.03.2020
Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (139KB)
Management / Finance
Jan.31.2020
Announcement on Financial Results for FY2019 3Q
R&D
Jan.24.2020
ONO Announces Result from Phase III Clinical Study Evaluating Opdivo® (Nivolumab) in Patients with Platinum-Refractory Advanced or Recurrent Ovarian Cancer (113KB)
CSR
Jan.20.2020
ONO Selected as a "Climate Change A List" Company in CDP 2019 for Two Consecutive Years (215KB)
R&D
Jan.16.2020
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbfs Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer (116KB)
R&D
Jan.06.2020
Ono and Seikagaku Submit a New Drug Application for Manufacturing and Marketing Approval for ONO-5704/SI-613 for the Treatment of Osteoarthritis in Japan (207KB)